In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compound

ACS Chemical Biology

Volumn 7, Issue 11, 2012, Pages 1866-1872

  Keating, Thomas A ^a   Newman, Joseph V ^a   Olivier, Nelson B ^a   Otterson, Linda G ^a   Andrews, Beth ^a   Boriack Sjodin, P Ann ^a   Breen, John N ^a   Doig, Peter ^a   Dumas, Jacques ^a   Gangl, Eric ^a   Green, Oluyinka M ^a   Guler, Satenig Y ^a   Hentemann, Martin F ^a   Joseph Mccarthy, Diane ^a   Kawatkar, Sameer ^a   Kutschke, Amy ^a   Loch, James T ^a   McKenzie, Andrew R ^a   Pradeepan, Selvi ^a   Prasad, Swati ^a   Martínez Botella, Gabriel ^a,b   more..

^a ASTRAZENECA   (United Kingdom)

^b Sage Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL DNA; BACTERIAL ENZYME; THYMIDINE PHOSPHATE; THYMIDYLATE KINASE; TK 666; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MODELS, MOLECULAR; NUCLEOSIDE-PHOSPHATE KINASE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MURINAE; POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 84869438365     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb300316n     Document Type: Article

References (21)

1. Fischbach, M. A. and Walsh, C. T. (2009) Antibiotics for emerging pathogens Science 325, 1089-1093
2. Payne, D. J., Gwynn, M. N., Holmes, D. J., and Pompliano, D. L. (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery Nat. Rev. Drug Discovery 6, 29-40
3. Wang, J., Soisson, S. M., Young, K., Shoop, W., Kodali, S., Galgoci, A., Painter, R., Parthasarathy, G., Tang, Y. S., Cummings, R., Ha, S., Dorso, K., Motyl, M., Jayasuriya, H., Ondeyka, J., Herath, K., Zhang, C., Hernandez, L., Allocco, A., Basilio, A., Tormo, J. R., Genilloud, O., Vicente, F., Palaez, F., Colwell, L., Lee, S. H., Michael, B., Felcetto, T., Gil, C., Silver, L. L., Hermes, J. D., Bartizal, K., Barrett, J., Schmatz, D., Becker, J. W., Cully, D., and Singh, S. B. (2006) Platensimycin is a selective FabF inhibitor with potent antibiotic properties Nature 441, 358-360
4. Andries, K., Verhasselt, P., Guillemont, J., Goehlmann, H. W. H., Neefs, J.-M., Winkler, H., Gestel, J. V., Timmerman, P., Zhu, M., Lee, E., Williams, P., Chaffoy, D. d., Huitric, E., Hoffner, S., Cambau, E., Truffot-Pernot, C., Lounis, N., and Jarlier, V. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 307, 223-227
5. Haydon, D. J., Stokes, N. R., Ure, R., Galbraith, G., Bennett, J. M., Brown, D. R., Baker, P. J., Barynin, V. V., Rice, D. W., Sedelnikova, S. E., Heal, J. R., Sheridan, J. M., Aiwale, S. T., Chauhan, P. K., Srivastava, A., Taneja, A., Collins, I., Errington, J., and Czaplewski, L. G. (2008) An inhibitor of FtsZ with potent and selective anti-staphylococcal activity Science 321, 1673-1675
6. +-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo Antimicrob. Agents Chemother. 55, 1088-1096
7. O'Neill, A. J. and Chopra, I. (2004) Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques Expert Opin. Investig. Drugs 13, 1045-1063
8. Petit, C. M. and Koretke, K. K. (2002) Characterization of Streptococcus pneumoniae thymidylate kinase: steady-state kinetics of the forward reaction and isothermal titration calorimetry Biochem. J. 363, 825-831
9. Zaritsky, A., Woldringh, C. L., Einav, M., and Alexeeva, S. (2006) Use of thymine limitation and thymine starvation to study bacterial physiology and cytology J. Bacteriol. 188, 1667-1679
10. Vanheusden, V., Munier-Lehmann, H., Froeyen, M., Busson, R., Rozenski, J., Herdewijn, P., and Calenbergh, S. V. (2004) Discovery of bicyclic thymidine analogues as selective and high-affinity inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase J. Med. Chem. 47, 6187-6194
11. Brundiers, R., Lavie, A., Veit, T., Reinstein, J., Schlichting, I., Ostermann, N., Goody, R. S., and Konrad, M. (1999) Modifying human thymidylate kinase to potentiate azidothymidine activation J. Biol. Chem. 274, 35389-35292
12. Choi, J. Y., Plummer, M. S., Starr, J., Desbonnet, C. R., Soutter, H., Chang, J., Miller, J. R., Dillman, K., Miller, A. A., and Roush, W. R. (2012) Structure guided development of novel thymidine mimetics targeting Pseudomonas aeruginosa thymidylate kinase: from hit to lead generation J. Med. Chem. 55, 852-870
13. Kotaka, M., Dhaliwal, B., Ren, J., Nichols, C. E., Angell, R., Lockyer, M., Hawkins, A. R., and Stammers, D. K. (2006) Structures of S. aureus thymidylate kinase reveal an atypical active site configuration and an intermediate conformational state upon substrate binding Protein Sci. 15, 774-784
14. Ostermann, N., Schlichting, I., Brundiers, R., Konrad, M., Reinstein, J., Veit, T., Goody, R. S., and Lavie, A. (2000) Insights into the phosphoryltransfer mechanism of human thymidylate kinase gained from the crystal structures of enzyme complexes along the reaction coordinate Structure 8, 629-642
15. Lavie, A., Ostermann, N., Brundiers, R., Goody, R. S., Reinstein, J., Konrad, M., and Schlichting, I. (1998) Structural basis for efficient phosphorylation of 3′-azidothymidine monophosphate by Escherichia coli thymidylate kinase Proc. Natl. Acad. Sci. U.S.A. 95, 14045-14050
16. CLSI (2009) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Eighth ed., document M07-A8, Clinical and Laboratory Standards Institute, Wayne, PA.
17. CLSI (1999) Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline, document M26-A, Clinical and Laboratory Standards Institute, Wayne, PA.
18. Pankey, G. A. and Sabath, L. D. (2004) Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections Clin. Infect. Dis. 38, 864-870
19. Hilliard, J. J., Goldschmidt, R. M., Licata, L., Baum, E. Z., and Bush, K. (1999) Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems Antimicrob. Agents Chemother. 43, 1693-1697
20. Schneider, T., Kruse, T., Wimmer, R., Wiedemann, I., Sass, V., Pag, U., Jansen, A., Nielsen, A. K., Mygind, P. H., Raventós, D. S., Neve, S., Ravn, B., Bonvin, A. M. J. J., Maria, L. D., Andersen, A. S., Gammelgaard, L. K., Sahl, H.-G., and Kristensen, H.-H. (2010) Plectasin, a fungal defensin, targets the bacterial cell wall precursor lipid II Science 328, 1168-1172
21. Balani, S. K., Li, P., Nguyen, J., Cardoza, K., Zeng, H., Mu, D.-X., Wu, J.-T., Gan, L.-S., and Lee, F. W. (2004) Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling Drug Metab. Dispos. 32, 1092-1095